Few studies evaluated the risk of ATB in patients with rheumatic diseases under treatment of AZA, a systematic review of randomized controlled trials found that the risk of ATB reactivation was higher when anti-TNF agents were combined with AZA as compared with anti-TNF monotherapy (OR = 13.3, p <0.001) [33]. The gene discussed is TNF; the disease is rheumatic disorder.